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Abstract
Background: Although adolescent and young adult (AYA) cancers are characterized by biological features and
clinical outcomes distinct from those of other age groups, the molecular profile of AYA cancers has not been well
defined. In this study, we analyzed cancer genomes from rare types of metastatic AYA cancers to identify driving
and/or druggable genetic alterations.
Methods: Prospectively collected AYA tumor samples from seven different patients were analyzed using three
different genomics platforms (whole-exome sequencing, whole-transcriptome sequencing or OncoScan™). Using
well-known bioinformatics tools (bwa, Picard, GATK, MuTect, and Somatic Indel Detector) and our annotation
approach with open access databases (DAVID and DGIdb), we processed sequencing data and identified driving
genetic alterations and their druggability.
Results: The mutation frequencies of AYA cancers were lower than those of other adult cancers (median = 0.56),
except for a germ cell tumor with hypermutation. We identified patient-specific genetic alterations in candidate
driving genes: RASA2 and NF1 (prostate cancer), TP53 and CDKN2C (olfactory neuroblastoma), FAT1, NOTCH1, and
SMAD4 (head and neck cancer), KRAS (urachal carcinoma), EML4-ALK (lung cancer), and MDM2 and PTEN (liposarcoma).
We then suggested potential drugs for each patient according to his or her altered genes and related pathways. By
comparing candidate driving genes between AYA cancers and those from all age groups for the same type of cancer,
we identified different driving genes in prostate cancer and a germ cell tumor in AYAs compared with all age groups,
whereas three common alterations (TP53, FAT1, and NOTCH1) in head and neck cancer were identified in both groups.
Conclusion: We identified the patient-specific genetic alterations and druggability of seven rare types of AYA cancers
using three genomics platforms. Additionally, genetic alterations in cancers from AYA and those from all age groups
varied by cancer type.
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Background
Cancer is one of the leading causes of death world-
wide. Abnormal genetic alterations followed by the
uncontrolled growth of somatic cells initiate cancer.
Although most genetic alterations are passenger
mutations that do not contribute to tumorigenesis,
an individual cell can proliferate and become a
tumor if it acquires a sufficient set of driving muta-
tions. Therefore, finding cancer-driving mutations
and targeting the encoded abnormal proteins and re-
lated pathways via cancer therapeutics are important
strategies to delay cancer progression and prevent
metastasis [1].
Previous studies, led by The Cancer Genome Atlas
(TCGA) and International Cancer Genome Consortium
(ICGC), have identified cancer-driving mutations via
large-scale analyses [2]. Although large-scale analyses
unveiled frequently altered driving mutations in many
cancer types, such as BRAF (V600E) in melanoma and
colorectal cancer, finding less frequently altered muta-
tions is a challenge using large-scale analyses, especially
in uncommon cancer types [2–4].
Adolescent and young adult (AYA) cancer is a rare
type of malignant disease that arises in patients aged
15 to 39 years and is characterized by biological
features, therapeutic outcomes, and survival rates that
are distinct from those observed in other age groups.
Although determining the genomic profiles of AYA
cancer is important to investigate the causes of these
distinct characteristics, large-scale genomic studies or
molecular data for AYA cancer are not available due
to the rarity of the disease and the difficulty of col-
lecting tumor samples [5, 6].
In this study, we analyzed seven different AYA
cancers from patients with metastatic tumors using
three different genomics platforms (whole-exome
sequencing, whole-transcriptome sequencing, and
OncoScan™). We identified single nucleotide variations
(SNVs) and insertion and deletions (indels) by using
whole-exome sequencing (WES) and detected fusions
by using whole transcriptome sequencing (WTS). For
copy number variations (CNVs), we used OncoScan™
that is the genomics platform for analysis of copy
number variations which had high performance with
samples from FFPE, especially [7]. We processed the
WES data with well-known bioinformatics tools (bwa,
Picard, GATK, MuTect, and Somatic Indel Detector),
as other studies described and processed WTS data
with fusion detection tools [8–10]. We then identified
candidate genes and suggested potential drugs that
are specific to the genetic alterations of each patient.
We also compared candidate genes for AYA cancers
with the same types of cancers from all age groups
using published data.
Methods
Ethics and consent statement
This study was approved by the Institutional Review
Board (IRB) of Seoul National University Hospital
(1206-086-414). We obtained written informed consent
from the patients who participated to this study. All
participants in this study gave us written informed con-
sent for publication of their details. Written informed
consent for publication of their clinical details and/or
clinical images was obtained from the patients. A copy
of the consent form is available for review by the Editor
of this journal.
Study design and sample information
Samples from seven different tumors, prostate cancer,
olfactory neuroblastoma, head and neck squamous cell
carcinoma (HNSCC), urachal carcinoma, germ cell
tumor, lung cancer, and liposarcoma, were prospectively
obtained in three different forms (fresh-frozen tissue,
formalin-fixed paraffin-embedded (FFPE), and pleurisy).
The samples were analyzed using three different genom-
ics platforms (whole-exome sequencing (WES), whole
transcriptome sequencing (WTS), and OncoScan™) as
the tumor sources permitted. We first intended to
analyze samples from ten patients, but three samples
were excluded because the amount of provided tumor
sample was insufficient (AYA03) or sufficient DNA/
RNA for a genome-scale analysis was not obtained
(AYA05, and 08). For sample AYA04 (HNSCC), the
HPV infection status was identified by IHC staining
(data not shown).
Whole exome sequencing (WES)
A minimum of 3 μg of genomic DNA was randomly
fragmented by Covaris, and the sizes of the library
fragments were mainly distributed between 250 and
300 bp. adapters were then ligated to both ends of
the fragments. Extracted DNA was amplified by
ligation-mediated PCR (LM-PCR) and then purified
and hybridized to the SureSelect XT Human All Exon
v4 + UTR 71 Mb (Agilent Technologies, Santa Clara,
CA, USA) for enrichment according to the manufac-
turer’s recommended protocol. After loading each
captured library on the Hiseq2000 platform (Illumina,
San Diego, CA, USA), we performed high-throughput
sequencing for each captured library. Raw image files
were processed by Illumina CASAVA v1.8.2 for base-
calling with default parameters, and the sequences
from each individual were generated as 101-bp pair-
end reads.
Processing WES data to analyze SNVs and indels
WES data were processed using a series of steps. We
aligned the sequenced files (Fastq file) to the reference
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genome (human reference genome g1k v37) using the
Burrows-Wheeler Aligner (BWA v0.7.5a) [11] and then
sorted the output and removed PCR duplicates using
PICARD v1.95 [12]. Using the typical GATK workflow
(The Genome Analysis Toolkit v2.6-5), we processed the
data for local indel realignment and base quality recali-
bration [13]. For variant calling, we used MuTect v1.1.6
for single nucleotide variants (SNVs) and Somatic Indel
Detector (from GATK v2.2-8) for indels [14]. Whereas we
called the SNVs with the default setting value, we altered
the tumor indel fraction from 0.3 to 0.05 (T_INDEL_F
<0.05) for indel calling after considering false-negatives.
The called variants interpreted as somatic mutations were
tagged with “KEEP” or “SOMATIC” with MuTect and
Somatic Indel Detector, respectively, and used for further
study. To avoid false-positive indel variants, we filtered
out variants with tumor alterative reads less than 6. All
somatic variants were annotated by ANNOVAR [15]. The
variants that passed through the steps were called ‘proc-
essed WES data’ (Additional file 1: Figure S1).
Analysis of copy number variations (CNVs) by OncoScan™
We used the 330-k OncoScan™ FFPE platform (Affyme-
trix, Santa Clara, CA, USA) to identify candidate CNVs
(amplification/deletion and loss-of-heterozygosity (LOH)).
AYA02 was excluded because the amount of DNA was
insufficient for OncoScan™. A minimum of 80 ng of DNA
from each sample was used for the OncoScan™ platform.
The Nexus Express (Affymetrix) software was used to
analyze the data and find CNVs. We filtered out CNVs
with a CN ≤ 2.5, which were considered insignificant
amplification, and analyzed chromosome-level CNVs and
focal level CNVs.
Analysis of CNVs by VarScan2 for AYA02
To analyze CNVs in AYA02, we used VarScan2 as an
alternative method to OncoScan™. After processing data
up to the ‘Realignment/Recalibration’ step in WES
processing (Additional file 1: Figure S1), we processed
data based on the manufacturer’s recommendations. We
generated mpileup data from recalibrated BAM files of
both tumor and normal using SAMtools and used the
‘Copy caller’ module of VarScan2 to generate the relative
copy number change (C), which was determined as
follows: C = log2 ((DT/DN)*(IN/IT)), where ‘D’ stands for
the average depth, ‘I’ for the number of uniquely mapped
bases, ‘N’ for normal, and ‘T’ for tumor [16, 17]. After
filtering out mapping quality values <15, we adjusted the
relative copy number using the re-centering option in
‘Copy caller’ and segmented copy number regions based
on the circular binary segmentation algorithm. After mer-
ging, the results were represented by IGV (Integrative
Genomics Viewer) [18]. Because the VarScan2 results cov-
ered only exon regions, not all genome regions, we
analyzed only chromosome-level CNVs that were similar
to those obtained with OncoScan™ and did not analyze
focal-level CNVs. To create graphs of relative copy num-
ber changes, we used data from re-centered relative copy
number changes displayed on a log2 scale.
Analysis of mutation frequency and mutation spectrum
The mutation frequency was analyzed by counting the
number of variants annotated by ANNOVAR from WES
data as nonsynonymous SNVs, synonymous SNVs, non-
sense mutations, stop-loss mutations, splicing mutations,
frameshift insertions/deletions (indels), in-frame indels,
and noncoding RNA in exonic regions. These mutations
had previously been described in published data from 12
major cancer studies [19]. To analyze the mutation
spectrum, we used SNVs processed with MuTect in all
sequenced regions not limited to coding regions.
Pathway-drug analysis
After assigning the levels to the variants by pattern-based
heuristic annotation, we investigated the biologic path-
ways of variants using DAVID or the literature [20]. To
analyze the druggability of the variants, we concentrated
mainly on level-1 (strong) variants using DGIdb [21].
Fusion analysis
We analyzed WTS data from four samples (AYA01, 02,
09, and 10) to identify cancer driving fusions using three
different fusion tools, FusionMap, deFuse and Chimer-
aScan [22–24]. From the results, we selected candidate
cancer-driving fusions using a fusion gene list archived
in COSMIC (download date: 2015-03-03).
Results
AYA cancer samples, platforms and generation of data
from WES
Samples analyzed in this study were collected from AYA
patients (median age = 32) who had metastatic tumors.
Seven different tumor samples were obtained in three
different forms (fresh-frozen tissues, FFPE and pleurisy)
and analyzed using three different genomics platforms
(WES, WTS and OncoScan™) (Table 1).
We processed WES data using well-known bioinfor-
matics tools described in Supporting Fig. 1 following
previously published studies [8, 10]. From the WES data
of six tumors and matched normal blood, we generated
total of 95 gigabases (Gb, range 12.5–20.0/sample) and
106 Gb (range 12.7–27.0/sample) of mapped sequences,
respectively. The mean target coverage was 135X (range,
101X-190X) and 150X (range, 115X-205X) for tumor
samples and normal blood, respectively. The coverage
of mean target bases exceeded 30X for 89.8 and
92.5 % of the tumor and normal blood samples,
respectively (Additional file 2: Table S1).
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Fig. 1 Mutation frequency and mutation spectrum of AYA cancers. a Somatic mutation frequencies of pediatric, AYA and adult cancers are
shown. Mutation frequencies of AYA cancers were assessed using somatic mutations annotated as nonsynonymous SNVs, synonymous SNVs,
nonsense mutations, stop-loss mutations, splicing mutations, frameshift indels, in-frame indels, and noncoding RNA. Mutation frequencies for
other cancers were derived from published data from the same regions [19]. b The mutation spectrum of AYA cancers (transition and
transversion frequency) was assessed using SNVs processed with MuTect in whole-exome regions
Table 1 Sample information of AYAs cancer patients




#01 30 M Prostate cancer Fresh-frozen Docetaxel + Pd v v v
#02 30 M Olfactory neuroblastoma Fresh-frozen ICE v v -
Op
PORT
#04 33 M Head and neck squamous
cell carcinoma






#06 32 M Urachalcarcinoma FFPE Op v - v
#07 21 M Germ cell tumor Fresh-frozen Op v - v
BEP
IE
#09 34 M Lung cancer Pleurisy - - v -
#10 33 M Liposarcoma Fresh-frozen Op v v v
a#03: exclusion, because of no tumor sample provided; #05, 08: exclusion, because of insufficient sample to sequencing
bPd prednisolone, ICE ifosfamide + carboplatin + etoposide, Op operation, PORT postoperative radiotherapy, CCRT concurrent chemoradiotherapy, DP docetaxel +
cisplatin, FP 5-fluorouracil + cisplatin, BEP bleomycin + etoposide + cisplatin, IE ifosfamide + etoposide
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Mutation frequency and mutation spectrum
We analyzed the mutation frequency and mutation
spectrum of six samples from processed WES data
(Fig. 1). Except for AYA07, which contained a hyper-
mutation, the coding regions (exon and splicing regions)
of a total of 276 somatic mutations (median, 40; range,
26–133) were detected (Additional file 3: Table S2).
Compared with the mutation frequency of 12 major
cancer types obtained from published data, the somatic
mutation frequency of most samples was low (median,
0.56/Mb; range, 0.37–1.87), except for AYA07 (Fig. 1a)
[19]. This finding is consistent with data showing that
somatic mutations are accumulated with age [1].
Although the mutation frequency of AYA07 was high
(9.37/Mb), the overall mutation frequency of AYA can-
cers is low: a recent large-scale study of testicular germ
cell tumors (TGCTs), the same tumor type as that of
AYA07, demonstrated a low mutation frequency (mean
0.5/Mb) [25]. Additionally, three AYA cancers with
higher mutation frequencies (AYA02, 04, and 07) har-
bored mutations in TP53 or in several DNA repair genes
compared with other samples (mean, 3.98/Mb vs. 0.44/
Mb, respectively), as shown in large studies [19].
Except for AYA07, the mutation spectrum of AYA
cancers showed prominent C > T transitions, as has been
demonstrated in many solid cancers (Fig. 1b) [26]. Inter-
estingly, AYA07 showed a high proportion of C > A
transversions (79.7 %). This result may be related to an
over-representation of C > A transversions in the TCGT
study [25] or multiple cycles of chemotherapy for the
AYA07 patient, because increased C > A transversions
were observed in all samples obtained from eight
relapsed AML patients after chemotherapy [27].
Individual AYA cancer analysis: patient-specific genetic
alterations
After processing the WES data, we annotated variants
using ANNOVAR as described in Additional file 1:
Figure S1. All annotated variants are described in
Additional file 4: Table S3. We then selected driving
genetic alterations using our pattern-based annotation,
because it is limited to analyzing rare types of cancers
using the same statistical methods to select driving
genetic alterations used in large-scale studies (Additional
file 3: Figure S2) [4]. By applying our approach to TCGA
AML data, we could detect all candidate genes that were
previously defined using statistical methods (Additional
file 3: Figure S3 and Additional file 5: Table S4) [28].
Except for the hypermutations in AYA07, we fo-
cused on level-1 variants to identify driving genetic
alterations of AYA cancers that are specific to each
patient and may be druggable (Fig. 2 and Additional
file 6: Table S5). CNVs were analyzed to identify can-
didate driving CNVs (OncoScan™) and chromosome-
level CNVs (OncoScan™ or VarScan2) (Fig. 3 and
Additional file 1: Figure S4).
AYA01, prostate cancer: aberrant activation of the RAS
pathway
AYA01 showed concurrent loss-of-function in genes of
the RasGAP family (NF1 and RASA2). A frameshift dele-
tion and LOH were detected in NF1, and a frameshift
insertion and splicing mutation were detected in RASA2
that were validated by sequencing (Additional file 1:
Figure S5). Interestingly, concurrent mutations in Ras-
GAPs have been identified in several types of cancers ac-
cording to the cBio portal (Additional file 1: Figure S6
and Additional file 7: Table S6). Furthermore, a recent
study demonstrated the synergistic oncogenic effects of
non-canonical Ras mutations in the context of loss-of-
function in RasGAP [29]. Because RasGAPs contribute
to tumorigenesis, we suggested an MEK inhibitor (as a
single agent or in combination) for the treatment of
AYA01 [30, 31].
AYA02, olfactory neuroblastoma: chromosome instability
and loss-of-function of CDKN2C
AYA02 harbored a chromosome-level alteration with a
TP53 missense mutation that contributed to chromo-
some instability [32]. Interestingly, AYA02 showed a
double peak of a relative copy number change and arm-
level alterations, which differed from other tumors
(Fig. 3a and b). A loss-of-function in CDKN2C was iden-
tified with high-allelic frequency (0.667). Given the
tumor suppressor function of CDKN2C in breast
cancer, a loss-of-function of CDKN2C may have
driven tumor formation in AYA02; therefore, we
selected CDK4/6 inhibitors as a potential drug (palbo-
ciclib and LY2835219) [33].
AYA04, HNSCC: alteration of the Wnt and NOTCH pathways
AYA04 harbored TP53 mutations with alterations in
FAT1, NOTCH1 and SMAD4 that have been recurrently
discovered by several large-scale studies of head and
neck cancer [34–36]. Specifically, AYA04 harbored con-
current mutations in Wnt pathway genes, such as FAT1,
MSX1 and AXIN1, which were reported in a recent
large-scale study of HNSCC with HPV (−) [34]. We sug-
gested potential drugs (LGK974 and γ secretase inhibi-
tor) for AYA04 based on the importance of the Wnt and
NOTCH pathways.
AYA06, urachal carcinoma: alteration in noted KRAS
mutation
Because AYA06 showed only one level-1 variant in
KRAS (G13D) with no candidate CNVs, we selected an
MEK inhibitor (selumetinib) as a potential drug. How-
ever, a missense mutation in USP6 (R133K, Lv2 OG)
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was detected in AYA06 and AYA04. USP6 is known
to be able to initiate tumorigenesis either in cell lines
or in mice via the activation of the NF-κB pathway,
although the function of the R133K variant remains
elusive [37].
AYA07, germ cell tumor: alteration in DNA repair genes and
genome instability
AYA07 was excluded from the identification of candi-
date driving genetic alterations, because AYA07 showed
a high mutation frequency with many CNVs may be
caused by missense mutations in six DNA repair genes
(DDB1, LIG3, MNAT1, POLE, POLG and POLQ) (Fig. 1
and Additional file 4: Table S3) [38]. The most fre-
quently mutated gene, KIT, which was found in a large-
scale study of TGCT, was not detected in AYA07 [25].
AYA09, lung cancer: well-known fusion, EML4-ALK
AYA09 was analyzed by WTS only because an IHC result
for ALK was positive (data not shown). Because the
EML4-ALK detected in our fusion processing is well
known in lung cancer, crizotinib and ceritinib were recom-
mended as potential drugs for AYA09 (Additional file 1:
Figure S6 and Additional file 8: Table S7). The patient was
treated with crizotinib and showed clinically significant
tumor shrinkage, as expected.
AYA10, liposarcoma: amplification of MDM2 with PTEN
deletion
Although level-1 SNV/indel alterations were not de-
tected, CNVs in MDM2 and PTEN, which play a role in
the p53 pathway, were identified in AYA10 (Fig. 3c).
Target-specific drugs for MDM2 amplification, DS-
3032b and RO6839921, plus an mTOR inhibitor, everoli-
mus, were recommended.
Comparison of candidate driving genes from AYA cancers
and cancers in other age groups
To investigate differences in the genomic profiles be-
tween AYA cancers and cancers found in other age
groups, we compared candidate driving genes between
AYAs and all age groups for the same cancer based on
published data from analyses similar to ours (Table 2).
The mutation pattern of AYA01 (prostate cancer) dif-
fered from that shown in a large-scale study analysis.
Whereas AYA01 harbored alterations in the Ras pathway
(NF1 and RASA2), prostate cancer from other age
groups showed recurrent mutations in SPOP, TP53, and
PTEN [39]. However, several commonly altered genes in
HNSCC, such as TP53, FAT1, and NOTCH1, were iden-
tified in both AYA04 and in large-scale studies, whereas
other mutations differed [34].
Fig. 2 Candidate driving genetic alterations and their druggability in AYA cancers. An analysis of WES/WTS and OncoScan™ with our heuristic
annotation identified level-1 candidate genetic alterations. By analyzing DAVID and DGIdb, the representative pathway of AYA cancers
and druggability were also identified. The druggability is indicated by illustrations of pills; red indicates a direct inhibitor of a candidate
target gene, and blue/yellow indicates an inhibitor of a pathway that includes the candidate alterations. AYA07 was excluded from the
candidate gene search due to the hypermutation. All candidate genetic alterations are described in Additional file 4: Table S3
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Discussion
Genomic profiling of AYA cancers
In this study, we described the genomic profiles of seven
different rare types of AYA cancers using three different
genomics platforms (WES, WTS and OncoScan™). After
processing genomics data, we identified potential
druggable targets for each cancer and selected exist-
ing anti-cancer drugs to treat individual patients
(Fig. 2 and Additional file 6: Table S5).
We identified candidate driving genetic alterations spe-
cific to each patient using logical manual curation (pat-
tern-based heuristic annotation) as alternative to statistical
method (Additional file 9: Supplementary materials and
methods and Additional file 10: Table S8). It is needed to
alternative method to select candidate genes in rare type
of cancers, like AYA cancers, since low number of samples
is limited to the selection of candidate driving genes using
statistical method as shown in large-scale studies [4].
Because the features of AYA cancers are distinct
from those of other age groups, including the
incidences and clinical outcomes, studying the gen-
omic profiles of AYA cancers is important to identify
the unique features of AYA cancers [5, 6]. When
comparing candidate genes between AYAs and all age
groups for the same cancer type, we identified differ-
ent candidate genes in prostate cancer (AYA01) and a
germ cell tumor (AYA07), although several common
candidate genes (TP53, FAT1,and NOTCH1) were
found in HNSCC (AYA04) in both AYAs and all age
groups (Table 2). These results showed that AYA-
specific genetic alterations may be different from
those in other age groups; thus, further study is
needed to define the significance of the differences in
the genetic alterations between AYAs and other age
groups.
Clinical implication
In this study, we analyzed individual cancer genomes
and suggested potential drugs for each patient based
on his or her genetic alterations. Characterizing the
Fig. 3 Analysis of CNVs in AYA cancers. a Distributions of relative copy number change (C) in AYA cancers, shown on a log2 scale. b Chromosome-
level alterations are shown and were processed by VarScan2. Similar patterns were detected by OncoScan™ (Additional file 1: Figure S3).
c OncoScan™ identified a focal amplification of MDM2 in AYA10
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genomes of patients and genomics-driven knowledge
enabled personalized medicine and advanced cancer
genomics for clinical implications [40]. Moreover, to
establish the clinical validity of genetic tests, espe-
cially for NGS data, the FDA discussed ‘post-market-
ing pursuit’ to define the clinical implications of
variants generated from NGS, which have remained
unknown [41]. Therefore, we expect many prospective
genomic studies, such as our study, to link the
patient to therapy as well as diagnosis, prognosis, and
monitoring [42].
Conclusion
We analyzed seven different metastatic AYA cancers’
genome, and potential targets were identified. Genetic
alterations in cancers from AYA and those from all age
groups were varied by their cancer type.
Table 2 Comparison of candidate driving genes of same cancer type from AYAs with those from all age group
Prostate cancer HNSCC
AYA01 Barbieri, et al. AYA04 TCGA
Sequencing platform WES (n = 1) WES (n = 112) WES (n = 1) WES (n = 279)
Exome capture kit Agilent SureSelect Agilent SureSelect Agilent SureSelect Agilent SureSelect
Sequencing instrument Illumina HiSeq Illumina HiSeq Illumina HiSeq Illumina HiSeq
Depth (mean) 138X 118X 198X 95X








Indels Somatic Indel Detector/Indelocator
Selection of candidate SNV/Indels Heuristic annotation MutSig Heuristic annotation MutSig
CNVs detection AffymetrixOncoScan Affymetrix SNP 6.0 AffymetrixOncoScan Affymetrix SNP 6.0
Selection of candidate CNVs Heuristic annotation GISTIC Heuristic annotation GISTIC
Candidate driving genes
SNVs/Indels NF1 SPOP TP53 CDKN2A
RASA2 TP53 FAT1 FAT1

















aEmphasized results from published paper (q < 0.0001)
bThere was not available emphasized result of CNVs
Cha et al. BMC Cancer  (2016) 16:170 Page 8 of 10
Additional files
Additional file 1: Figure S1. WES pipeline for our study. Figure S2.
Pattern-based heuristic annotation to identify driving genetic alterations.
Figure S3. Pattern-based heuristic annotation for large-scale samples.
Figure S4. Chromosome-level CNVs of AYA cancers from OncoScan™
and VarScan2. Figure S5. Sequencing validation of RASA2 and NF1 in
AYA01 sample. Figure S6. Concurrency of RasGAPs in large-scale studies.
Figure S7. EML4-ALK validation in AYA09 cells. (DOCX 50738 kb)
Additional file 2: Table S1. Sequencing information for WES data.
(PDF 95 kb)
Additional file 3: Table S2. Mutation frequency of WES data for AYA
cancers. (PDF 50 kb)
Additional file 4: Table S3. Processed WES data. (PDF 635 kb)
Additional file 5: Table S4. Patient-specific genetic alterations of TCGA
AML study selected by our pattern-based annotation. (PDF 156 kb)
Additional file 6: Table S5. Candidate driving genetic alterations of
AYA cancers. (PDF 150 kb)
Additional file 7: Table S6. RasGAPs in large-scale studies. (PDF 234 kb)
Additional file 8: Table S7. EML4-ALK fusion in AYA09. (PDF 128 kb)
Additional file 9: Supplementary materials and methods. (DOC 21 kb)
Additional file 10: Table S8. CVE list. (PDF 285 kb)
Abbreviation
AYA: adolescent and young adult; CNV: copy number variation;
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mediated PCR; NGS: next generation sequencing; SNV: single nucleotide
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WES: whole exome sequencing; WTS: whole transcriptome sequencing.
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